Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PLAT | P00750 | 2/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30408073 | 0.88 | LMNA (0.59) | MAPTTDP1PORCNCYP1A2ALDH1A1 | |
| SCHEMBL2197321 | 0.83 | ALDH1A1 (0.70) | MAPTTDP1CYP1A2ALDH1A1KDM4E | |
| SCHEMBL30407133 | 0.83 | ALDH1A1 (0.72) | MAPTTDP1PORCNALDH1A1KDM4E | |
| SCHEMBL1221576 | 0.82 | TSHR (0.67) | PLAUMAPTTDP1 | |
| SCHEMBL29410906 | 0.82 | TSHR (0.67) | PLAUMAPTTDP1 | |
| SCHEMBL9128923 | 0.81 | PORCN (0.60) | MAPTTDP1PORCNCYP1A2ALDH1A1 | |
| SCHEMBL3359577 | 0.80 | CA12 (0.65) | PLAUMAPTTDP1 | |
| Hydrochloric Acid SCHEMBL29506745 | 0.80 | CA12 (0.65) | PLAUMAPTTDP1 | |
| SCHEMBL30407560 | 0.80 | PORCN (0.69) | MAPTTDP1PORCNALDH1A1KDM4E | |
| SCHEMBL22223646 | 0.80 | PTPN1 (0.76) | PLAUMAPTPLATPLGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034112-A1 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | UNIV YALE (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023064458-A1 | SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | YALE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034112-A1 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | JAK2, JAK1, MCL1 | PLAU 3044/4885MAPT 4854/4885TDP1 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.